+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2026-2032- Product Image
Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Paroxysmal Nocturnal Hemoglobinuria Drugs Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6137324
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Paroxysmal Nocturnal Hemoglobinuria Drugs Market is projected to reach USD 4.43 Billion in 2026. It is expected to continue growing at a CAGR of 6.09%, reaching USD 6.24 Billion by 2032.

Paroxysmal Nocturnal Hemoglobinuria Drugs: Executive Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder caused by somatic mutations affecting glycosylphosphatidylinositol-anchored proteins. The resulting complement-mediated hemolysis, thrombosis risk, and bone-marrow failure create a clinically heterogeneous treatment environment. Drug management focuses on controlling intravascular and extravascular hemolysis, reducing transfusion requirements, preventing thrombotic complications, and addressing anemia and related symptoms. Treatment selection depends on disease severity, complement activity, renal status, prior therapy, pregnancy considerations, vaccination needs, and access to specialist care. Because PNH is uncommon and diagnostically complex, long-term outcomes depend on timely flow-cytometric confirmation, monitoring, adherence, and coordinated hematology management.

Treatment Is Shifting From Hemolysis Control Toward Broader Disease Management

The therapeutic landscape is moving beyond a single emphasis on intravascular hemolysis toward more complete control of complement activity and residual anemia. Clinicians increasingly distinguish between persistent symptoms caused by breakthrough hemolysis, extravascular hemolysis, iron imbalance, marrow failure, and unrelated comorbidities. This is encouraging more individualized treatment pathways, including reassessment after therapy initiation and consideration of mechanism, administration burden, infection risk, and patient preferences.

Care delivery is also becoming more structured. Diagnostic confirmation, vaccination and infection-risk mitigation, laboratory surveillance, thrombosis assessment, and renal monitoring are integral to treatment rather than separate activities. Access remains uneven because PNH requires specialized testing and sustained follow-up, while affordability, reimbursement, infusion capacity, and availability of trained hematologists influence whether patients can receive and remain on advanced therapies.

Artificial Intelligence Can Improve PNH Detection, Monitoring, and Care Coordination

Artificial intelligence may support PNH care by identifying suggestive patterns in longitudinal blood counts, hemolysis markers, transfusion histories, thrombosis records, and electronic health records. Such tools could help prioritize patients for confirmatory flow cytometry and flag changes that merit clinical review. AI-assisted interpretation may also help harmonize complex laboratory data across institutions, although diagnostic confirmation must remain grounded in validated testing and specialist judgment.

In treatment monitoring, predictive models could support early recognition of breakthrough hemolysis, transfusion needs, renal deterioration, or adherence barriers. These applications require carefully curated datasets because PNH is rare, coding practices vary, and underdiagnosis can create substantial selection bias. Governance should address privacy, explainability, external validation, inequitable performance across populations, and the risk that automated alerts increase workload without improving outcomes.

Regional Insights: Access and Specialist Capacity Define Treatment Experience

In North America, established hematology networks and access to advanced complement-directed care support comprehensive management, while reimbursement complexity, infusion logistics, and high out-of-pocket exposure can still affect continuity. Europe benefits from strong rare-disease infrastructure and cross-border clinical expertise, but access pathways and coverage criteria differ among countries. Asia-Pacific combines advanced centers with substantial variation in diagnostic capacity, specialist availability, and access outside major metropolitan areas.

Latin America faces uneven availability of flow cytometry, specialist referral, and sustained treatment funding, making delayed diagnosis and treatment interruption important concerns. The Middle East is developing rare-disease services, but capacity and reimbursement differ considerably across health systems. Africa generally encounters the greatest constraints in diagnostic access, specialist coverage, laboratory infrastructure, and long-term financing. Across all regions, referral networks, standardized protocols, patient registries, and telehematology can help reduce avoidable delays.

Group Insights: Economic and Health-System Coalitions Shape PNH Access

ASEAN countries show varied levels of specialist care, diagnostic infrastructure, and reimbursement, with major urban centers often serving as referral hubs. BRICS members combine substantial clinical capabilities with pronounced internal differences in public funding, geographic access, and availability of rare-disease testing. The European Union benefits from collaborative research and rare-disease policy mechanisms, although national assessment and reimbursement decisions continue to shape patient access.

G7 health systems generally have advanced diagnostic and hematology capacity, but treatment pathways remain influenced by regulatory review, payer policy, and regional service distribution. GCC countries often have concentrated specialist resources and the ability to develop coordinated rare-disease programs, while access can vary by residency and health-system eligibility. NATO membership does not create a single PNH pathway, but participating countries may share opportunities for clinical collaboration, laboratory standards, emergency preparedness, and specialist education.

Country Insights: National Pathways Vary in Diagnosis, Funding, and Specialist Reach

Australia and Canada have strong specialist capabilities but must address geographic dispersion and referral delays. The United States has extensive hematology expertise and advanced testing, while insurance design and treatment affordability can affect continuity. In Europe, France, Germany, Italy, Spain, and the United Kingdom have established rare-disease and hematology services, but national guidance, commissioning, reimbursement, and access arrangements differ. These differences influence diagnostic timing, site-of-care decisions, and follow-up models.

Japan and South Korea combine sophisticated healthcare systems with specialized hematology expertise, although approval, reimbursement, and diagnostic practices remain nationally specific. China and India have expanding clinical capacity but substantial variation between major centers and less-resourced regions. Brazil and Mexico face regional differences in specialist access, testing, and public-sector availability. Russia’s care environment is shaped by referral concentration, laboratory capacity, and national procurement arrangements. Across these countries, strengthening registries and standardized diagnostic pathways would improve visibility into untreated and undertreated patients.

Industry Priorities: Strengthen Diagnosis, Continuity, and Patient-Centered Evidence

Industry leaders should prioritize earlier recognition by supporting education on unexplained hemolysis, cytopenias, thrombosis, and transfusion dependence, while helping expand reliable flow-cytometry access. Partnerships with hematology centers, laboratories, patient organizations, and public health authorities can improve referral pathways without replacing independent clinical decision-making.

Treatment programs should address the full care journey: vaccination and infection-risk counseling, administration support, adherence services, laboratory monitoring, renal and thrombotic surveillance, and rapid evaluation of breakthrough symptoms. Evidence generation should include patient-reported outcomes, quality of life, real-world persistence, outcomes in underrepresented populations, pregnancy-related considerations, and settings with limited resources. Leaders should also use transparent value communication and responsible data governance when applying digital tools or AI.

Research Methodology: Evidence-Based Synthesis for a Rare Hematologic Disorder

This executive summary uses a structured secondary-research approach focused on authoritative clinical, regulatory, epidemiologic, and health-system evidence concerning PNH diagnosis and treatment. Relevant sources include peer-reviewed hematology literature, professional guidelines, public regulatory materials, rare-disease registries, government health information, and documented reimbursement or access frameworks. Findings are synthesized thematically across treatment evolution, care delivery, regional systems, country contexts, and responsible technology use.

Because PNH is rare and data availability varies, conclusions are framed around verified clinical and system-level patterns rather than market quantification. Country and regional comparisons are directional and recognize differences in terminology, testing practices, reporting completeness, and health-system organization. Claims should be refreshed as guidelines, regulatory decisions, clinical evidence, and national access policies change.

Conclusion: Better Outcomes Depend on Integrated, Equitable PNH Care

PNH management is becoming more individualized as clinicians address multiple mechanisms of hemolysis, marrow dysfunction, thrombosis, renal risk, symptoms, and treatment burden. Progress depends not only on effective medicines but also on rapid diagnosis, specialist coordination, sustained monitoring, infection-risk management, and dependable access.

The greatest opportunity is to connect advanced therapy with stronger health-system foundations. Expanded testing, referral networks, registries, patient support, and carefully validated digital tools can reduce diagnostic and treatment gaps. Regional and national differences will persist, but coordinated, evidence-based care can improve the consistency, safety, and patient-centeredness of PNH management.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Product
7.1. Introduction
7.2. Eculizumab
7.3. Ravulizumab
8. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Mechanism Of Action
8.1. Introduction
8.2. Complement C3 Inhibitor
8.3. Terminal Complement C5 Inhibitor
8.3.1. Eculizumab
8.3.2. Ravulizumab
9. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.2.1. Eculizumab
9.2.2. Ravulizumab
9.3. Subcutaneous Injection
10. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Paroxysmal Nocturnal Hemoglobinuria Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Akari Therapeutics PLC
16.2. Alexion Pharmaceuticals, Inc.
16.3. Alnylam Pharmaceuticals, Inc.
16.4. Amgen Inc.
16.5. Apellis Pharmaceuticals, Inc.
16.6. AstraZeneca PLC
16.7. BioCryst Pharmaceuticals, Inc.
16.8. CANbridge Pharmaceuticals, Inc.
16.9. CSL Behring AG
16.10. F. Hoffmann-La Roche AG
16.11. Genentech, Inc.
16.12. Kira Pharmaceuticals, Inc.
16.13. Novartis AG
16.14. NovelMed Therapeutics, Inc.
16.15. Omeros Corporation
16.16. Pfizer Inc.
16.17. Regeneron Pharmaceuticals, Inc.
16.18. Sanofi S.A.
16.19. Swedish Orphan Biovitrum AB
16.20. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market, Years Considered for the Study
FIGURE 2. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market, Research Design
FIGURE 3. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market, Research Framework
FIGURE 4. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market, Data Triangulation
FIGURE 5. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Segmentation & Coverage
TABLE 2. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Eculizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Ravulizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Ravulizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Ravulizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 11. Global Complement C3 Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Complement C3 Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Complement C3 Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Terminal Complement C5 Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Terminal Complement C5 Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Terminal Complement C5 Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Eculizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Ravulizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Ravulizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Ravulizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 24. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Eculizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Eculizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Eculizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Ravulizumab Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Ravulizumab Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Ravulizumab Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 37. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 47. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 65. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 67. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 68. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 69. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 70. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 71. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. North America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 75. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 76. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 77. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 78. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 79. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Latin America Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 83. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 84. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 85. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 86. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 87. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Europe Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 89. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 91. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 92. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 93. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 94. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 95. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Middle East Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 97. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 99. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 100. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 101. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 102. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 103. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Africa Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 108. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 109. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 110. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 111. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 112. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. ASEAN Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 116. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 117. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 118. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 119. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 120. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. GCC Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 122. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 124. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 125. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 126. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 128. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. European Union Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 132. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 133. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 134. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 135. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 136. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. BRICS Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 140. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 141. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 142. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 144. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. G7 Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 148. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 149. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 150. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 151. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 152. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. NATO Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 155. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 156. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 157. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 158. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 159. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 160. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 161. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. United States Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 163. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 164. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 165. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 166. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 167. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 168. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 169. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. Canada Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 172. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 173. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 174. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 175. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 176. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 177. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Mexico Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 179. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 180. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 181. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 182. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 183. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 185. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Brazil Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 188. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 189. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 190. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 191. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 192. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 193. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 196. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 197. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 198. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 199. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 200. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 201. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. Germany Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 204. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 205. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 206. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 207. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 208. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 209. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. France Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 212. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 213. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 214. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 215. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 216. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 217. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. Russia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 219. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 220. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 221. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 222. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 223. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 225. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Italy Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 227. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 228. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 229. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 230. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 231. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 233. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Spain Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 236. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 237. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 238. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 239. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 241. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. China Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 244. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 245. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 246. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 247. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 248. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 249. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. India Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 251. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 252. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 253. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 254. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 255. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 256. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 257. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. Japan Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 260. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 261. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 262. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 263. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 264. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 265. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Australia Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, 2017-2032 (USD Million)
TABLE 268. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Product, 2017-2032 (USD Million)
TABLE 269. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 270. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Terminal Complement C5 Inhibitor, 2017-2032 (USD Million)
TABLE 271. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Intravenous Infusion, 2017-2032 (USD Million)
TABLE 273. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. South Korea Paroxysmal Nocturnal Hemoglobinuria Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market Share, by Key Player, 2025
TABLE 276. Global Paroxysmal Nocturnal Hemoglobinuria Drugs Market, Key Experts

Companies Mentioned

  • Akari Therapeutics PLC
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • BioCryst Pharmaceuticals, Inc.
  • CANbridge Pharmaceuticals, Inc.
  • CSL Behring AG
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Kira Pharmaceuticals, Inc.
  • Novartis AG
  • NovelMed Therapeutics, Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032 - Product Image

Paroxysmal Nocturnal Hemoglobinuria Treatment Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Paroxysmal Nocturnal Hemoglobinuria - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 169 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment - Global Strategic Business Report

  • Report
  • 126 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report 2026 - Product Image

Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Paroxysmal Nocturnal Hemoglobinuria (Pnh) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Paroxysmal Nocturnal Hemoglobinuria (Pnh) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.